- Home
- ECBK vs EQ Comparison
ECBK vs EQ Comparison
Compare ECBK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | EQ |
|---|---|---|
| Founded | 1919 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 151.5M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ECBK | EQ |
|---|---|---|
| Price | $20.36 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 5.2K | ★ 423.3K |
| Earning Date | 05-12-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | $598,000.00 | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.94 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $0.76 |
| 52 Week High | $21.51 | $3.54 |
Technical Indicators
Market Signals| Indicator | ECBK | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 44.14 |
| Support Level | $17.76 | $2.15 |
| Resistance Level | N/A | $2.58 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 100.00 | 10.00 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.